NKTR · Company research
Nektar Therapeutics (NKTR): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry? | Nektar Therapeutics (NKTR) initiated two Phase III studies (ZENITH AD-1 and ZENITH AD-2) for rezpeg in atopic dermatitis in July 2026, with top-line data expected mid-2028. The company plans Phase III studies for alopecia areata in early 2027 and expects Type I diabetes data in 2027. Rezpeg, a self-administered injection that activates regulatory T-cells, faces competition from established players like Sanofi/Regeneron's Dupixent. NKTR trades at a valuation discount to the industry with a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.5 | 1 |
| Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry? | Nektar Therapeutics (NKTR) initiated two Phase III studies (ZENITH AD-1 and ZENITH AD-2) for rezpeg in atopic dermatitis in July 2026, with top-line data expected mid-2028. The company plans Phase III studies for alopecia areata in early 2027 and expects Type I diabetes data in 2027. Rezpeg, a self-administered injection that activates regulatory T-cells, faces competition from established players like Sanofi/Regeneron's Dupixent. NKTR trades at a valuation discount to the industry with a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.5 | 1 |
| Leerink Highlights Nektar Therapeutics (NKTR) as Top Emerging Te - GuruFocus | Leerink Highlights Nektar Therapeutics (NKTR) as Top Emerging Te GuruFocus | View source ↗ | GuruFocus | Oct 12, 2026 | neutral | 0 | 0.6 |
| Nektar Therapeutics (NKTR) Could Be 71% Undervalued As Rezpegaldesleukin Data Extend Its Case - Yahoo Finance | Nektar Therapeutics (NKTR) Could Be 71% Undervalued As Rezpegaldesleukin Data Extend Its Case Yahoo Finance | View source ↗ | Yahoo Finance | Oct 12, 2026 | neutral | 0 | 0.6 |
| Nektar Therapeutics (NasdaqCM:NKTR) Stock Forecast & Analyst Predictions - Simply Wall Street | Nektar Therapeutics (NasdaqCM:NKTR) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 12, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Oct 12, 2026 | neutral | 0 | 0.6 |
| Nektar Therapeutics (NKTR) stock price, news, quote and history - Yahoo Finance UK | Nektar Therapeutics (NKTR) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 8, 2026 | neutral | 0 | 0.6 |
| Nektar Therapeutics (NKTR) stock price, news, quote and history - Yahoo Finance Singapore | Nektar Therapeutics (NKTR) stock price, news, quote and history Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 8, 2026 | neutral | 0 | 0.6 |
| NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge - Stocktwits | NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge Stocktwits | View source ↗ | Stocktwits | Oct 1, 2026 | neutral | 0 | 0.6 |
| Nektar Posted Promising Alopecia Results. Here's Why It Took A 22% Beating. - Investor's Business Daily | Nektar Posted Promising Alopecia Results. Here's Why It Took A 22% Beating. Investor's Business Daily | View source ↗ | Investor's Business Daily | Oct 1, 2026 | neutral | 0 | 0.6 |
| Nektar Therapeutics (NKTR) Stock Dropped, So What Is Driving Attention Now? - Simply Wall Street | Nektar Therapeutics (NKTR) Stock Dropped, So What Is Driving Attention Now? Simply Wall Street | View source ↗ | Simply Wall Street | Sep 28, 2026 | neutral | 0 | 0.6 |
| 11 new hires got rights to buy 58,600 shares, plus 2,450 stock awards from Nektar. - Stock Titan | 11 new hires got rights to buy 58,600 shares, plus 2,450 stock awards from Nektar. Stock Titan | View source ↗ | Stock Titan | Sep 25, 2026 | neutral | 0 | 0.6 |
| Nektar Therapeutics (NKTR) Stock Slides As Cash Burn Clouds Pipeline Progress - Simply Wall Street | Nektar Therapeutics (NKTR) Stock Slides As Cash Burn Clouds Pipeline Progress Simply Wall Street | View source ↗ | Simply Wall Street | Aug 16, 2026 | neutral | 0 | 0.6 |
| Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch - Yahoo Finance | Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch Yahoo Finance | View source ↗ | Yahoo Finance | Aug 14, 2026 | neutral | 0 | 0.6 |
| Nektar Therapeutics Reports First Quarter 2026 Financial Results - PR Newswire | Nektar Therapeutics Reports First Quarter 2026 Financial Results PR Newswire | View source ↗ | PR Newswire | May 7, 2026 | neutral | 0 | 0.6 |
| Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PR Newswire | Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire | View source ↗ | PR Newswire | Apr 23, 2026 | neutral | 0 | 0.6 |
| Nektar Therapeutics Announces Proposed Public Offering - PR Newswire | Nektar Therapeutics Announces Proposed Public Offering PR Newswire | View source ↗ | PR Newswire | Apr 20, 2026 | neutral | 0 | 0.6 |
| Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering - PR Newswire | Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering PR Newswire | View source ↗ | PR Newswire | Feb 11, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.